Article
The FDA has approved Merck Human Health's dorzolomide HCI (Trusopt) ophthalmic solution 2% for use in pediatric patients. The drug is used to treat elevated IOP in patients with ocular hypertension or open-angle glaucoma.
Factors affecting ROP development in the 8 weeks following birth
ROP: Treating and preventing blindness in preterm babies
ASU researchers tap AI to help people see more clearly
Managing a changing landscape of IRD pediatric cases
Faster identification of infants at high risk of ROP by evaluating the effects of maternal and fetal vascular malperfusion
Alcon Children’s Vision Center recipient of 10th Annual Bonnie Strickland Champion for Children’s Vision Award